Publikationen, an denen er mitarbeitet Maria Bryszewska (23)

2024

  1. A new class of polyphenolic carbosilane dendrimers binds human serum albumin in a structure-dependent fashion

    Scientific Reports, Vol. 14, Núm. 1

  2. Effect of polyphenolic dendrimers on biological and artificial lipid membranes

    Chemistry and Physics of Lipids, Vol. 265

  3. Polyphenolic dendrimers as carriers of anticancer siRNA

    International Journal of Pharmaceutics, Vol. 658

2023

  1. Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study

    International Journal of Pharmaceutics, Vol. 636

  2. Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

  3. Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocols

    Colloids and Surfaces B: Biointerfaces, Vol. 227

  4. Ruthenium metallodendrimer against triple-negative breast cancer in mice

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 53

2022

  1. Heterofunctionalized polyphenolic dendrimers decorated with caffeic acid: Synthesis, characterization and antioxidant activity

    Sustainable Materials and Technologies, Vol. 33

2021

  1. Cationic Carbosilane Dendrimers Prevent Abnormal α-Synuclein Accumulation in Parkinson's Disease Patient-Specific Dopamine Neurons

    Biomacromolecules, Vol. 22, Núm. 11, pp. 4582-4591

  2. Combined therapy of ruthenium dendrimers and anti-cancer drugs against human leukemic cells

    Dalton Transactions, Vol. 50, Núm. 27, pp. 9500-9511

2020

  1. Copper (II) metallodendrimers combined with pro-apoptotic sirnas as a promising strategy against breast cancer cells

    Pharmaceutics, Vol. 12, Núm. 8, pp. 1-14

  2. Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer

    European Journal of Medicinal Chemistry, Vol. 199

  3. Heterofunctional ruthenium(II) carbosilane dendrons, a new class of dendritic molecules to fight against prostate cancer

    European Journal of Medicinal Chemistry, Vol. 207

  4. Ruthenium dendrimers against human lymphoblastic leukemia 1301 cells

    International Journal of Molecular Sciences, Vol. 21, Núm. 11, pp. 1-13

2019

  1. In vitro anticancer properties of copper metallodendrimers

    Biomolecules, Vol. 9, Núm. 4

  2. Synthesis and characterization of FITC labelled ruthenium dendrimer as a prospective anticancer drug

    Biomolecules, Vol. 9, Núm. 9

2017

  1. Binding of poly(amidoamine), carbosilane, phosphorus and hybrid dendrimers to thrombin—Constants and mechanisms

    Colloids and Surfaces B: Biointerfaces, Vol. 155, pp. 11-16

2012

  1. Carbosilane dendrimers are a non-viral delivery system for antisense oligonucleotides: Characterization of dendriplexes

    Journal of Biomedical Nanotechnology, Vol. 8, Núm. 1, pp. 57-73

2011

  1. Carbosilane dendrimers NN8 and NN16 form a stable complex with siGAG1

    Colloids and Surfaces B: Biointerfaces, Vol. 83, Núm. 2, pp. 388-391

2009

  1. Binding properties of water-soluble carbosilane dendrimers

    Journal of Fluorescence, Vol. 19, Núm. 2, pp. 267-275